Although African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research concentrates on people of European descent in association with the disease, reports study led by researchers at the Keck School of Medicine of USC.
That trend is problematic considering that African-Americans -- the most at-risk population for multiple myeloma -- have different genetics that can affect how this type of cancer progresses and what kind of targeted therapies are most effective, said Zarko Manojlovic, lead author of the study.
Multiple Myeloma
Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Mehta's 'Water' , declared that she had the incurable Multiple Myeloma.
Advertisement
‘While European have mutations in the TP53 gene, African-Americans are susceptible to mutations in BCL7A, a different tumor suppressor gene.’
Tweet it Now
For example, in the study, multiple myeloma patients of European descent were six times more likely than their African peers to have mutations in the TP53 gene, a tumor suppressor that helps prevent cancer. African-Americans, on the other hand, experienced heightened mutations in BCL7A, a different tumor suppressor gene.
"A cancer therapy that targets TP53 would not be as effective for African-Americans with multiple myeloma as it would be for a white population because doctors would be trying to fix the wrong mutated gene," said Manojlovic, assistant professor of research translational genomics at the Keck School of Medicine.
![New Therapeutic Approach can Help Treat Multiple Myeloma]( "New Therapeutic Approach can Help Treat Multiple Myeloma")
Multiple myeloma is a cancer that grows in bone, and in most patients it is associated with widespread bone loss, and recurrent bone fractures.
The study was published in PLOS Genetics. Researchers analyzed the genetic sequencing data of 718 multiple myeloma patients and found that African-Americans had increased mutations in the genes BCL7A, BRWD3 and AUTS2, while white people had more mutations in the genes TP53 and IRF4.
The study is the largest and most ethnically diverse genomics study of multiple myeloma to date, the researchers said.
The scientists genetically analyzed the ancestry for all patients and found that 127 patients were of African descent and 591 were of European descent.
"There are clearly molecular differences between African-American and Caucasian multiple myeloma cases, and it will be critical to pursue these observations to better improve clinical management of the disease for all patients," said John D. Carpten, senior author of the study and chair of the Department of Translational Genomics at the Keck School of Medicine.
Higher incidence rate and lower survival rates for African-Americans
Multiple myeloma is a cancer of plasma cells in the blood that causes tumor growths in bone marrow. About 30,280 people will be diagnosed with the cancer this year, and about half of them will survive longer than five years, according to the National Cancer Institute.
African-Americans are two times more likely than white people to die from multiple myeloma, the study stated.
"In the past decade, new treatments for the disease have spurred a remarkable improvement in survival for myeloma patients, but those benefits have disproportionately increased survival rates for Caucasian patients," Carpten said. "African-American multiple myeloma patients have higher incidence rates and lower survival rates than their Caucasian peers despite this being a relatively easy-to-treat cancer.
"We in the cancer genomics community have a responsibility to ensure that our studies represent true population diversity so we can understand the role of ancestry and biology in health outcomes. The new candidate myeloma genes we identified in the African-American population may have been overlooked because of the lack of diversity in previous genomic efforts."
Source: Eurekalert
New Therapeutic Approach can Help Treat Multiple Myeloma
Multiple myeloma is a cancer that grows in bone, and in most patients it is associated with widespread bone loss, and recurrent bone fractures.
Advertisement
The study was published in PLOS Genetics. Researchers analyzed the genetic sequencing data of 718 multiple myeloma patients and found that African-Americans had increased mutations in the genes BCL7A, BRWD3 and AUTS2, while white people had more mutations in the genes TP53 and IRF4.
The study is the largest and most ethnically diverse genomics study of multiple myeloma to date, the researchers said.
The scientists genetically analyzed the ancestry for all patients and found that 127 patients were of African descent and 591 were of European descent.
"There are clearly molecular differences between African-American and Caucasian multiple myeloma cases, and it will be critical to pursue these observations to better improve clinical management of the disease for all patients," said John D. Carpten, senior author of the study and chair of the Department of Translational Genomics at the Keck School of Medicine.
Higher incidence rate and lower survival rates for African-Americans
Multiple myeloma is a cancer of plasma cells in the blood that causes tumor growths in bone marrow. About 30,280 people will be diagnosed with the cancer this year, and about half of them will survive longer than five years, according to the National Cancer Institute.
African-Americans are two times more likely than white people to die from multiple myeloma, the study stated.
"In the past decade, new treatments for the disease have spurred a remarkable improvement in survival for myeloma patients, but those benefits have disproportionately increased survival rates for Caucasian patients," Carpten said. "African-American multiple myeloma patients have higher incidence rates and lower survival rates than their Caucasian peers despite this being a relatively easy-to-treat cancer.
"We in the cancer genomics community have a responsibility to ensure that our studies represent true population diversity so we can understand the role of ancestry and biology in health outcomes. The new candidate myeloma genes we identified in the African-American population may have been overlooked because of the lack of diversity in previous genomic efforts."
Source: Eurekalert
Multiple Myeloma Linked to Defective 'protein Factory'
Defects in the ribosome of multiple myeloma patients have been discovered by researchers.
Advertisement
 Multiple Myeloma Patients Benefit from Treatment at More Experienced CentersPeople diagnosed with multiple myeloma are more likely to live longer if they are treated at a medical center that sees many patients with this blood cancer. | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
HR positive/HER2 negative breast cancer is the most common subtype of the disease and accounts for nearly 70% of breast cancer cases in the Unites States.
An antibody treatment helped shrink tumors in some patients with bile duct cancers.
Comprehending the association between the gut microbiome and polyp growth sheds insights into potential screenings and treatments.
The first large-scale, collaborative, open analysis of genomic data provides a cloud-based resource for researchers looking for more comprehensive data on pediatric brain tumors.
The mission of Axiom Space incorporated numerous experiments focusing on human stem cell aging, inflammation, and cancer within the laboratory situated in the low Earth orbit.